CO2019014592A2 - Neurotoxina botulínica para el tratamiento de trastornos asociados a la hiperactividad de melanocito y/o exceso de melanina - Google Patents

Neurotoxina botulínica para el tratamiento de trastornos asociados a la hiperactividad de melanocito y/o exceso de melanina

Info

Publication number
CO2019014592A2
CO2019014592A2 CONC2019/0014592A CO2019014592A CO2019014592A2 CO 2019014592 A2 CO2019014592 A2 CO 2019014592A2 CO 2019014592 A CO2019014592 A CO 2019014592A CO 2019014592 A2 CO2019014592 A2 CO 2019014592A2
Authority
CO
Colombia
Prior art keywords
treatment
disorders associated
botulinum neurotoxin
excess melanin
melanocyte hyperactivity
Prior art date
Application number
CONC2019/0014592A
Other languages
English (en)
Inventor
Birgitte P S Jacky
Shiazah Z Malik
Joanne Wang
Yi Liu
Amy Brideau-Andersen
Lance E Steward
Linh Q Le
Edward C Hsia
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CO2019014592A2 publication Critical patent/CO2019014592A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Abstract

Se proporcionan métodos para tratar afecciones de la piel relacionadas con la hipermelanina, como la hiperpigmentación. Los métodos comprenden administrar una composición que comprende BoNT/DC.
CONC2019/0014592A 2017-05-31 2019-12-23 Neurotoxina botulínica para el tratamiento de trastornos asociados a la hiperactividad de melanocito y/o exceso de melanina CO2019014592A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762512792P 2017-05-31 2017-05-31
PCT/US2018/035025 WO2018222652A1 (en) 2017-05-31 2018-05-30 Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin

Publications (1)

Publication Number Publication Date
CO2019014592A2 true CO2019014592A2 (es) 2020-06-09

Family

ID=62683456

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0014592A CO2019014592A2 (es) 2017-05-31 2019-12-23 Neurotoxina botulínica para el tratamiento de trastornos asociados a la hiperactividad de melanocito y/o exceso de melanina

Country Status (16)

Country Link
US (3) US10912823B2 (es)
EP (1) EP3630298A1 (es)
JP (1) JP7096845B2 (es)
KR (1) KR20200011499A (es)
CN (1) CN110891594A (es)
AU (1) AU2018277754A1 (es)
BR (1) BR112019025402A2 (es)
CA (1) CA3065542A1 (es)
CL (1) CL2019003484A1 (es)
CO (1) CO2019014592A2 (es)
IL (1) IL270986B (es)
MX (1) MX2019014349A (es)
PH (1) PH12019502721A1 (es)
RU (1) RU2019143639A (es)
WO (1) WO2018222652A1 (es)
ZA (1) ZA201907916B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2755815T3 (es) 2016-09-13 2020-04-23 Allergan Inc Composiciones de toxina de Clostridium no proteicas estabilizadas
WO2018222652A1 (en) * 2017-05-31 2018-12-06 Allergan, Inc. Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
KR20210097530A (ko) * 2020-01-30 2021-08-09 (주)메디톡스 Snare 복합체의 형성을 저해하는 펩티드, 및 그의 용도
KR102550756B1 (ko) * 2022-12-21 2023-07-05 (주)메디톡스 세포로부터 신경전달물질 분비를 저해하는 펩티드, 및 그의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
CN100525831C (zh) * 2002-12-20 2009-08-12 肉毒素研究同仁股份有限公司 改进的药用肉毒杆菌毒素组合物
EP1599213A4 (en) * 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8048423B2 (en) 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
GB0820970D0 (en) * 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US9744237B2 (en) * 2009-01-29 2017-08-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
WO2012103415A1 (en) * 2011-01-28 2012-08-02 Allergan, Inc. Dosage regimen for the treatment of multiple disorders with botulinum toxins
US20140276359A1 (en) * 2013-03-15 2014-09-18 Plum Systems Co. Apparatus and method for tissue rejuvenation
JP6608357B2 (ja) * 2013-06-28 2019-11-20 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞において神経毒ポリペプチドの生物活性を決定する手段及び方法
WO2015024503A1 (en) * 2013-08-21 2015-02-26 The Hong Kong Polytechnic University Engineering clostridia neurotoxins with elevated catalytic activity
WO2016048689A1 (en) * 2014-09-23 2016-03-31 Avidas Pharmaceuticals Llc Delivery and induction of therapeutic agents and uses thereof
AU2017360346B2 (en) * 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
WO2018222652A1 (en) * 2017-05-31 2018-12-06 Allergan, Inc. Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
RU2020123343A (ru) * 2017-12-20 2022-01-20 Аллерган, Инк. Полипептиды клеточносвязывающего домена ботулинического токсина и способы применения для омоложения кожи

Also Published As

Publication number Publication date
RU2019143639A (ru) 2021-06-30
ZA201907916B (en) 2021-05-26
AU2018277754A1 (en) 2020-01-02
MX2019014349A (es) 2020-07-28
EP3630298A1 (en) 2020-04-08
CA3065542A1 (en) 2018-12-06
IL270986B (en) 2021-07-29
IL270986A (en) 2020-01-30
WO2018222652A1 (en) 2018-12-06
CL2019003484A1 (es) 2020-05-15
US20210162027A1 (en) 2021-06-03
KR20200011499A (ko) 2020-02-03
US20230302103A1 (en) 2023-09-28
BR112019025402A2 (pt) 2020-06-23
US20180344820A1 (en) 2018-12-06
RU2019143639A3 (es) 2021-09-06
PH12019502721A1 (en) 2020-10-19
US10912823B2 (en) 2021-02-09
JP7096845B2 (ja) 2022-07-06
JP2020522492A (ja) 2020-07-30
CN110891594A (zh) 2020-03-17

Similar Documents

Publication Publication Date Title
CO2019014592A2 (es) Neurotoxina botulínica para el tratamiento de trastornos asociados a la hiperactividad de melanocito y/o exceso de melanina
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
ECSP19075354A (es) Moduladores de k-ras
CL2018001897A1 (es) Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509)
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
BR112017012377A2 (pt) conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
BR112018001292A2 (pt) métodos para melhor liberação de agentes ativos a tumores
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX2018007266A (es) Combinaciones para el tratamiento del cancer.
DOP2021000130A (es) Moduladores de la expresion de hsd17b13
CL2019002427A1 (es) Inhibición de smarca2 para el tratamiento de cáncer.
BR112017005282A2 (pt) produtos para tratamento de pele
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
BR112016025333A2 (pt) agente, produto e uso
BR112018068293A2 (pt) malassezina e seus análogos como agentes de clareamento de pele
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
AR107263A1 (es) Composiciones cosméticas para la reparación cutánea
BR112018074820A2 (pt) surfactantes não iónicos para a redução de tecido adiposo